पोमालिडोमाइड के इंटरैक्शन

Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (पोमालिडोमाइड लेबल, दवाओं के इंटरैक्शन)

Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (पोमालिडोमाइड लेबल, दवाओं के इंटरैक्शन)

Treatment of patients with MM with a PD-1 or PD-L1 blocking antibody in combination with a thalidomide analogue plus dexamethasone is not recommended outside of controlled clinical trials. (पोमालिडोमाइड लेबल, चेतावनियां और सावधानियां)

Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (पोमालिडोमाइड लेबल, दवाओं के इंटरैक्शन)

Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (पोमालिडोमाइड लेबल, दवाओं के इंटरैक्शन)

Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (पोमालिडोमाइड लेबल, दवाओं के इंटरैक्शन)

Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (पोमालिडोमाइड लेबल, दवाओं के इंटरैक्शन)

Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (पोमालिडोमाइड लेबल, दवाओं के इंटरैक्शन)

Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (पोमालिडोमाइड लेबल, दवाओं के इंटरैक्शन)

In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (पोमालिडोमाइड लेबल, चेतावनियां और सावधानियां)

In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (पोमालिडोमाइड लेबल, चेतावनियां और सावधानियां)

Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (पोमालिडोमाइड लेबल, चेतावनियां और सावधानियां)

In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (पोमालिडोमाइड लेबल, चेतावनियां और सावधानियां)

In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (पोमालिडोमाइड लेबल, चेतावनियां और सावधानियां)

Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (पोमालिडोमाइड लेबल, चेतावनियां और सावधानियां)

Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (पोमालिडोमाइड लेबल, चेतावनियां और सावधानियां)

In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (पोमालिडोमाइड लेबल, चेतावनियां और सावधानियां)

Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (पोमालिडोमाइड लेबल, चेतावनियां और सावधानियां)

Patients with known risk factors, including prior thrombosis, may be at greater risk, and actions should be taken to try to minimize all modifiable factors (e.g., hyperlipidemia, hypertension, smoking). (पोमालिडोमाइड लेबल, चेतावनियां और सावधानियां)

Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (पोमालिडोमाइड लेबल, चेतावनियां और सावधानियां)

Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (पोमालिडोमाइड लेबल, चेतावनियां और सावधानियां)

Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (पोमालिडोमाइड लेबल, चेतावनियां और सावधानियां)

Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (पोमालिडोमाइड लेबल, चेतावनियां और सावधानियां)

In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (पोमालिडोमाइड लेबल, चेतावनियां और सावधानियां)

In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (पोमालिडोमाइड लेबल, चेतावनियां और सावधानियां)

In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (पोमालिडोमाइड लेबल, चेतावनियां और सावधानियां)

Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (पोमालिडोमाइड लेबल, चेतावनियां और सावधानियां)

In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (पोमालिडोमाइड लेबल, चेतावनियां और सावधानियां)

In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (पोमालिडोमाइड लेबल, चेतावनियां और सावधानियां)